Prenatal Opioid Exposure Linked to Vision and Attention Problems in Children

Children exposed to opioids before birth carry higher risks of vision defects, attention problems and weaker school performance well into adolescence, according to a systematic review that pooled 27 studies covering more than 31,000 exposed children. The analysis, led by the University of Glasgow with the University of Dundee and published July 21 in the journal Addiction, is the most comprehensive attempt yet to describe what happens to these children between the ages of five and 18 — long after the newborn period that has dominated research on the subject.

The authors are careful about what the evidence can and cannot say. This is a review of associations, not a demonstration of cause, and the children in it grew up amid poverty, instability and other exposures that are hard to disentangle from the drugs themselves. But the consistency of the pattern across countries and study designs is the finding: the same handful of problems keeps surfacing wherever researchers look.

What the review pulled together

Most of what clinicians know about prenatal opioid exposure concerns the first weeks of life — low birth weight and neonatal opioid withdrawal, the tremors and feeding difficulties that follow delivery. The school years have been studied far less consistently, in scattered cohorts using different measures.

The Glasgow team gathered a decade of that scattered work: 27 research papers spanning Europe, North America, Australasia and Asia, comparing more than 31,000 children with a history of prenatal opioid exposure against over 5.4 million children without one, across 10 countries. "Exposure" was defined broadly, and that breadth matters for how the results should be read. It included illicit opioid use during pregnancy, medications for opioid use disorder such as methadone and buprenorphine, and diagnoses of neonatal withdrawal — three very different situations folded into one category.

The vision findings are the clearest

The most consistent signal was in the eyes. Across the studies, children exposed to opioids in the womb showed higher rates of strabismus, or eye misalignment; nystagmus, the involuntary flicking movement of the eyes; and reduced visual acuity. Vision is not usually on the list of things pediatricians watch for in these children, which is part of why the authors flagged it.

The pattern is not new to the Glasgow group. A 2023 observational cohort from the same research community found that children born to mothers on methadone maintenance were nearly twice as likely as their peers to have significant visual abnormalities by primary-school age. The new review shows that result was not a local quirk — similar visual problems turn up in cohort after cohort, in different health systems and with different opioids.

Attention, learning and a widening gap

The second cluster of findings sits in the classroom. Exposed children showed more hyperactivity and inattention, including a higher likelihood of being diagnosed with attention-deficit/hyperactivity disorder, along with differences in memory, verbal IQ and overall educational attainment.

Most striking was the trajectory over time. Rather than narrowing as children got older, the gaps appeared to widen: some studies found children with prenatal opioid exposure were roughly twice as likely to fall below expected standards in literacy and numeracy by early adolescence. That is the opposite of what a purely newborn-period problem would predict, and it points toward developmental needs that outlast infancy by many years.

Findings on physical health, brain development and emotional wellbeing were more mixed, and the authors were explicit that those areas need more study before anything can be concluded.

Association is not the same as cause

The single most important caveat runs through the entire paper. A systematic review can show that two things travel together; it cannot prove one produced the other, and it cannot separate the drug from the life around it.

"While we cannot say that prenatal opioid exposure directly causes these outcomes — and we have limited data on factors such as dosage, timing, and type of opioid exposure — the consistency of findings, particularly around vision, attention and learning, suggests that these children may face increased developmental challenges as they grow older," said Dr. Louise Marryat, a senior research fellow at Glasgow's School of Health and Wellbeing who led the work.

Families affected by opioid use disorder often contend with poverty, housing instability, trauma and co-occurring conditions, any of which can shape a child's vision, attention or reading independently of medication taken during pregnancy. Because the review lumped illicit use together with prescribed treatment and with withdrawal diagnoses, it cannot tell families which of those exposures — if any — is driving the numbers.

Why the treatment message matters

That distinction is not academic, and the researchers went out of their way to head off the wrong conclusion: pregnant women should not change how they take prescribed opioids without talking to their doctor first.

Methadone and buprenorphine are the standard of care for opioid use disorder in pregnancy for a reason. Stopping them abruptly can trigger withdrawal that is dangerous to a fetus and frequently sends a parent back to an unregulated drug supply — an outcome worse on every measure than staying in treatment. A finding that exposed children need closer developmental follow-up is an argument for supporting those families, not for pushing them off medication that keeps them alive. Rainier Rehab covered that trade-off directly when researchers examined extended-release buprenorphine during pregnancy earlier this summer.

Marryat framed the takeaway as one of support and monitoring. "Families affected by opioid use face complex challenges, and policy interventions that prioritise family-centred, supportive approaches can improve outcomes for these children," she said, calling for "joined-up support across health, education and social care" and for long-term developmental tracking so that vision and attention difficulties are caught early enough to help.

Alison McFadden, professor of mother and infant public health at the University of Dundee, said the review "highlights some of the long-term poor outcomes experienced by children who experienced prenatal opioid exposure," while stressing that "further research is needed to understand the full range of effects, especially for children over 12 years of age."

What comes next

The review draws a clearer map of where to look than of what to do. It cannot say how much opioid, at what point in pregnancy, or of what kind matters most, because the underlying studies rarely recorded those details. It also thins out after age 12, leaving the adolescent years — when the literacy and numeracy gaps seem to widen — the least understood.

For clinicians, the practical implication is narrower and more immediate: children with a history of prenatal opioid exposure may benefit from routine vision checks and from watching for attention and learning difficulties as they move through school, so that support arrives early rather than after a child has already fallen behind. The work was funded by a UK Research and Innovation Future Leaders Fellowship.